ArticleFrontiers in immunology2022

Efficacy and safety of CD19-specific CAR-T cell-based therapy in secondary central nervous system lymphoma.

Huanxin Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.